Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers ...Middle East

HONG KONG, GERMANTOWN, Md., and SUZHOU, China, Feb. 1, 2023 /PRNewswire/ -- Sirnaomics Ltd. (the "Company" or "Sirnaomics", stock code: 2257.HK), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that it is advancing the clinical...

Hence then, the article about sirnaomics accelerates clinical development of stp705 for the treatment of non melanoma skin cancers was published today ( Wednesday 01/02/2023 - 10:08 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Sirnaomics Accelerates Clinical Development of STP705 for the Treatment of Non-Melanoma Skin Cancers )

Also on site :

• China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
• Goldman Sachs expects layoffs to keep rising—and says investors are punishing the stocks of companies that slash staff
• Prominent Canadian Musician Says Gig Was Cancelled After Google AI Overview Wrongly Branded Him Sex Pest